FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Overview of attention for article published in Clinical Cancer Research, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

So far, Altmetric has seen 23 tweets from 21 users, with an upper bound of 627,993 followers.

RT @FDAOncology: FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors - via @CCR_AACR #OCEPu…

RT @FDAOncology: FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors - via @CCR_AACR #OCEPu…

RT @FDAOncology: FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors - via @CCR_AACR #OCEPu…

FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors - via @CCR_AACR #OCEPublications https://t.co/vOlJmruNI5

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 19 additional tweets.